Targeting the inflammatory pathway as a therapeutic tool for major depression

Neuroimmunomodulation. 2014;21(2-3):131-9. doi: 10.1159/000356549. Epub 2014 Feb 14.

Abstract

In the last decades convergent findings from several lines of evidence has revealed a robust association between major depressive disorder (MDD) and inflammatory pathways. Despite this, the translation of these findings into new and better treatments for MDD has not occurred. The objective of this study is to comprehensively review what is already known with reasonable certainty on inflammatory pathways in MDD, to clarify some points that have been insufficiently studied and to discuss the implications of these findings for future studies targeting inflammatory pathways as a therapeutic tool for individuals with MDD.

Publication types

  • Review

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology
  • Antioxidants / pharmacology
  • Depressive Disorder, Major / complications*
  • Depressive Disorder, Major / immunology
  • Depressive Disorder, Major / therapy
  • Humans
  • Inflammation / complications*
  • Inflammation / immunology
  • Inflammation / therapy

Substances

  • Anti-Inflammatory Agents
  • Antioxidants